Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ClaPd in Relapsed or Refractory Multiple Myeloma
NCT01159574Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Aug 2010
- Primary completion
- May 2015
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pomalidomide in multiple myeloma (MM), sponsored by Weill Cornell Medicine. Primary endpoint: Overall Response Rate. Started Aug 2010; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01159574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01159574.